MCID: TNG004
MIFTS: 41

Tongue Disease

Categories: Gastrointestinal diseases, Oral diseases, Smell/Taste diseases

Aliases & Classifications for Tongue Disease

MalaCards integrated aliases for Tongue Disease:

Name: Tongue Disease 12 15
Abnormality of the Tongue 30 6
Tongue Diseases 45 74
Tongue Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:10944
ICD9CM 36 529.9
MeSH 45 D014060
SNOMED-CT 69 69244009
ICD10 34 K14 K14.9
UMLS 74 C0040409

Summaries for Tongue Disease

MedlinePlus : 44 Your tongue helps you taste, swallow, and chew. You also use it to speak. Your tongue is made up of many muscles. The upper surface contains your taste buds. Problems with the tongue include Pain Swelling Changes in color or texture Abnormal movement or difficulty moving the tongue Taste problems These problems can have many different causes. Treatment depends on the underlying problem.

MalaCards based summary : Tongue Disease, also known as abnormality of the tongue, is related to ankyloglossia and muscular dystrophy, limb-girdle, autosomal recessive 5, and has symptoms including snoring, halitosis and oral manifestations. An important gene associated with Tongue Disease is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Pathways in cancer and DNA Damage Response (only ATM dependent). The drugs Doxycycline and Cefuroxime have been mentioned in the context of this disorder. Affiliated tissues include tongue and colon.

Wikipedia : 77 Tongue diseases can be congenital or acquired, and are multiple in number. Considered according to a... more...

Related Diseases for Tongue Disease

Diseases related to Tongue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 ankyloglossia 10.8
2 muscular dystrophy, limb-girdle, autosomal recessive 5 10.8
3 cerebral convexity meningioma 10.5 CDH1 TP53
4 adult hepatocellular carcinoma 10.5 CTNNB1 TP53
5 vulvar intraepithelial neoplasia 10.5 MMP2 TP53
6 bladder squamous cell carcinoma 10.5 CDKN2A TP53
7 bartholin's gland benign neoplasm 10.4 CDKN2A SLC10A2
8 large intestine adenocarcinoma 10.4 CDH1 CTNNB1
9 infiltrating angiolipoma 10.4 CDKN2A VEGFC
10 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
11 bartholin's gland disease 10.4 CDKN2A SLC10A2 TP53
12 tonsil cancer 10.4 CDH1 CDKN2A TP53
13 pre-malignant neoplasm 10.4 CDH1 CDKN2A TP53
14 in situ carcinoma 10.4 CDH1 CDKN2A TP53
15 cholecystitis 10.4 CDH1 CDKN2A TP53
16 ovarian cancer 1 10.4 CDH1 MMP2 TP53
17 malignant ovarian surface epithelial-stromal neoplasm 10.4 CDH1 MMP2 TP53
18 bladder disease 10.4 CDH1 CDKN2A TP53
19 ovary epithelial cancer 10.4 CDH1 MMP2 TP53
20 psammomatous meningioma 10.4 CTNNB1 MMP2
21 gallbladder adenoma 10.4 CDKN2A CTNNB1
22 actinic keratosis 10.4 CDKN2A MMP2 TP53
23 laryngeal squamous cell carcinoma 10.4 CDH1 CDKN2A TP53
24 cell type benign neoplasm 10.4 CDKN2A CTNNB1 TP53
25 anaplastic thyroid cancer 10.4 CDH1 CTNNB1 TP53
26 supratentorial cancer 10.4 CDKN2A MMP2 TP53
27 cerebrum cancer 10.4 CDKN2A MMP2 TP53
28 male reproductive organ cancer 10.4 CDH1 CTNNB1 TP53
29 epstein-barr virus-associated gastric carcinoma 10.4 CDH1 CDKN2A CTNNB1
30 colonic disease 10.4 CDH1 CTNNB1 TP53
31 spitz nevus 10.4 CDKN2A TP53
32 colorectal adenocarcinoma 10.4 CDH1 CTNNB1 TP53
33 grade iii astrocytoma 10.4 CDKN2A MMP2 TP53
34 skin melanoma 10.4 CDKN2A MMP2 TP53
35 ureteral obstruction 10.4 CTNNB1 TP53 VEGFC
36 stomach disease 10.4 CDH1 CTNNB1 TP53
37 intrahepatic cholangiocarcinoma 10.4 CDH1 CTNNB1 TP53
38 uterine carcinosarcoma 10.4 CDH1 CTNNB1 TP53
39 goblet cell carcinoid 10.4 CDH1 CTNNB1
40 endometrial adenocarcinoma 10.4 CDKN2A CTNNB1 TP53
41 intestinal disease 10.4 CDH1 CTNNB1 TP53
42 oropharynx cancer 10.3 CD6 CDH1 CDKN2A TP53
43 bladder carcinoma in situ 10.3 CDKN2A TP53
44 suppression of tumorigenicity 12 10.3 CDH1 CTNNB1 TP53
45 vulva squamous cell carcinoma 10.3 CDKN2A TP53
46 melanoma, uveal 10.3 CDKN2A MMP2 VEGFC
47 cervix disease 10.3 CDH1 CDKN2A CTNNB1 TP53
48 cervical squamous cell carcinoma 10.3 CDH1 CDKN2A CTNNB1 TP53
49 uterine anomalies 10.3 CDH1 CDKN2A CTNNB1 TP53
50 transitional cell carcinoma 10.3 CDH1 CDKN2A TP53

Graphical network of the top 20 diseases related to Tongue Disease:



Diseases related to Tongue Disease

Symptoms & Phenotypes for Tongue Disease

UMLS symptoms related to Tongue Disease:


snoring, halitosis, oral manifestations, glossalgia, peeling tongue

Drugs & Therapeutics for Tongue Disease

Drugs for Tongue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 4,Not Applicable 564-25-0 54671203
2
Cefuroxime Approved Phase 4,Not Applicable 55268-75-2 5361202 5479529
3
Penicillin V Approved, Vet_approved Phase 4 87-08-1 6869
4
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
5 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2,Not Applicable
6 Anti-Infective Agents Phase 4,Phase 1,Phase 2,Not Applicable
7 Antimalarials Phase 4,Not Applicable
8 Antiparasitic Agents Phase 4,Not Applicable
9 cefuroxime axetil Phase 4,Not Applicable
10 Antiprotozoal Agents Phase 4,Not Applicable
11 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2,Not Applicable
12 penicillins Phase 4
13
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124
14
Cisplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
15
Cetuximab Approved Phase 2, Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
16 Immunoglobulins Phase 2, Phase 3,Phase 1,Not Applicable
17 Antibodies Phase 2, Phase 3,Phase 1,Not Applicable
18 Immunologic Factors Phase 2, Phase 3,Phase 1,Not Applicable
19 Antimitotic Agents Phase 2, Phase 3,Phase 1
20 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 1,Not Applicable
21 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1,Not Applicable
22
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
23
leucovorin Approved Phase 2,Not Applicable 58-05-9 6006 143
24 Raspberry Approved Phase 1, Phase 2,Not Applicable
25
Carboplatin Approved Phase 2,Phase 1 41575-94-4 38904 10339178 498142
26
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
27
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
28
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 6436030 5284616
29
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
30
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
31
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
32
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
33
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
34
Histamine Approved, Investigational Phase 2 51-45-6 774
35
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
37
nivolumab Approved Phase 2 946414-94-4
38
Hydroxyurea Approved Phase 2,Phase 1 127-07-1 3657
39
Promethazine Approved, Investigational Phase 2 60-87-7 4927
40
Famotidine Approved Phase 2 76824-35-6 3325
41
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
42
Gliclazide Approved Phase 2 21187-98-4 3475
43
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
44
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
45
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
46
Inulin Approved, Investigational, Nutraceutical Phase 2 9005-80-5 24763
47
Saracatinib Investigational Phase 2 379231-04-6
48
Lapatinib Approved March 2007, Investigational Phase 2 388082-78-8, 231277-92-2 208908 9941095
49 Anesthetics Phase 2,Not Applicable
50 Central Nervous System Depressants Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome Completed NCT01518192 Phase 4 doxycycline;cefuroxime axetil
2 Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice Completed NCT01368341 Phase 4 Doxycycline;Phenoxymethylpenicillin;Amoxicillin
3 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
4 Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Unknown status NCT02985255 Phase 2 Docetaxel;Cisplatin;5FU
5 Inulin and S. Salivarius Reduce Halitosis Completed NCT02794766 Phase 2 Inulin+SS;S salivarius;Placebo
6 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
7 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
8 Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed NCT01195922 Phase 1, Phase 2 Sirolimus
9 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
10 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
11 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
12 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
13 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
14 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
15 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
16 Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Completed NCT00064103 Phase 1, Phase 2
17 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
18 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer Recruiting NCT03107182 Phase 2 nab-paclitaxel;Carboplatin;Nivolumab;Cisplatin;Hydroxyurea;5-FU;Dexamethasone;Famotidine;Diphenhydramine;Paclitaxel
19 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting NCT03602079 Phase 1, Phase 2 A166
20 S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Recruiting NCT03499808 Phase 2
21 Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
22 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Recruiting NCT03008330 Phase 1, Phase 2
23 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Recruiting NCT02849379 Phase 1, Phase 2
24 Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
25 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Active, not recruiting NCT02123511 Phase 2 acetylcysteine
26 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
27 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
28 A Study of Tongue Conservation Surgery for Oral Tongue Cancer Terminated NCT03161548 Phase 2 Induction chemotherapy
29 Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity Withdrawn NCT02295540 Phase 1, Phase 2
30 Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer Withdrawn NCT01953952 Phase 2 cisplatin
31 Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
32 Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel
33 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
34 TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck Completed NCT01334177 Phase 1 TLR8 agonist VTX-2337
35 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
36 Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Completed NCT00049283 Phase 1 erlotinib hydrochloride;docetaxel
37 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer Recruiting NCT01847326 Phase 1 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;fluorouracil;hydroxyurea
38 Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Terminated NCT01528137 Phase 1
39 Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Terminated NCT00906360 Phase 1 sunitinib malate
40 Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy Withdrawn NCT01728480 Phase 1 entolimod;cisplatin
41 Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy Withdrawn NCT01332279 Phase 1 everolimus;erlotinib hydrochloride
42 HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome Unknown status NCT01931293 Not Applicable
43 Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer Unknown status NCT01854021 Not Applicable
44 The Relationship Between Allergic Rhinitis and Geographic Tongue Unknown status NCT01454492
45 Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans Completed NCT03584919 Not Applicable doxycycline;Cefuroxime Axetil 500Mg Tab
46 Culture Media for Borrelia Burgdorferi Sensu Lato Completed NCT02145754 Not Applicable
47 Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High-Risk Appalachian Patients Previously Treated With Surgery For Oral Cancer Completed NCT01504932 Not Applicable lyophilized black raspberry lozenge
48 Doxycycline in Therapy of Erythema Migrans Completed NCT01475708 Doxycycline
49 Duration of Antibiotic Treatment of Erythema Migrans Completed NCT00910715 Not Applicable doxycycline;doxycycline;placebo
50 Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging Completed NCT00594724 Not Applicable

Search NIH Clinical Center for Tongue Disease

Cochrane evidence based reviews: tongue diseases

Genetic Tests for Tongue Disease

Genetic tests related to Tongue Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Tongue 30

Anatomical Context for Tongue Disease

MalaCards organs/tissues related to Tongue Disease:

42
Tongue, Colon

Publications for Tongue Disease

Articles related to Tongue Disease:

# Title Authors Year
1
Tongue disease in advanced AIDS. ( 15752079 )
2005

Variations for Tongue Disease

ClinVar genetic disease variations for Tongue Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
2 46;XY;t(3;17)(p14.3;q24.3)dn Translocation Likely pathogenic
3 DNAJC21 NM_194283.3(DNAJC21): c.544C> T (p.Arg182Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 5, 34937536: 34937536
4 DNAJC21 NM_194283.3(DNAJC21): c.544C> T (p.Arg182Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 5, 34937431: 34937431
5 SOX3 NM_005634.2(SOX3): c.735_737dupCGC (p.Ala248_Ser249insAla) duplication Uncertain significance rs398124211 GRCh38 Chromosome X, 140504324: 140504326
6 SOX3 NM_005634.2(SOX3): c.735_737dupCGC (p.Ala248_Ser249insAla) duplication Uncertain significance rs398124211 GRCh37 Chromosome X, 139586489: 139586491
7 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539

Expression for Tongue Disease

Search GEO for disease gene expression data for Tongue Disease.

Pathways for Tongue Disease

GO Terms for Tongue Disease

Cellular components related to Tongue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Tongue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 9.26 CDKN2A TP53
2 morphogenesis of embryonic epithelium GO:0016331 9.16 CTNNB1 VEGFC
3 entry of bacterium into host cell GO:0035635 8.96 CDH1 CTNNB1
4 cellular response to indole-3-methanol GO:0071681 8.62 CDH1 CTNNB1

Molecular functions related to Tongue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.8 CDKN2A CTNNB1 TP53

Sources for Tongue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....